Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ramius' Hostile Bid For Cypress Bioscience Has Unusual Twist

This article was originally published in The Pink Sheet Daily

Executive Summary

The hedge fund operator offers $154 million after Cypress' unpopular licensing of an anti-psychotic drug. But Ramius might want to share the upside on the drug after all.
Advertisement

Related Content

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Astellas Wins OSI But Victory Comes At A Price
Astellas Wins OSI But Victory Comes At A Price
CVT And Gilead Look To Lock Out Astellas With Planned Merger
CVT And Gilead Look To Lock Out Astellas With Planned Merger
Lilly Snatches ImClone Away From Bristol

Topics

Advertisement
UsernamePublicRestriction

Register

PS070918

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel